News Alert: Sanofi Is the Second Manufacturer to Appeal a 340B Contract Pharmacy Court Ruling

Drug manufacturer Sanofi is appealing a federal district judge’s Nov. 5 ruling in its 340B contract pharmacy lawsuit.

Drug manufacturer Sanofi today gave notice that it is appealing a federal district judge’s Nov. 5 orders and opinions in its 340B contract pharmacy lawsuit.

Sanofi’s one-sentence Nov. 19 notification to the federal government defendants and U.S. Chief District

Read More »

News Alert: HRSA Sets Wheels in Motion for a New 340B Administrative Dispute Resolution Proposed Rule

HRSA has asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation.

The U.S. Health Resources and Services Administration (HRSA) yesterday asked the White House to review and approve a 340B administrative dispute resolution (ADR) proposed regulation for publication in the Federal Register.

The proposed rule’s purpose is unknown. HRSA published a

Read More »

Appeals Court Raises Procedural Questions About Lilly’s 340B Contract Pharmacy Case

A federal appeals court is questioning whether a lower court's ruling in Lilly's 340B contract pharmacy suit is "ready for appellate review."

Drug manufacturer Lilly’s appeal of a federal district judge’s ruling late last month in the company’s 340B contract pharmacy lawsuit has hit a procedural snag.

In an unsigned pair of orders on Tuesday, the federal appeals court in Chicago questioned

Read More »

GOP Congressman Slams PBMs for Taking Away Safety Net Providers’ 340B Savings

Rep. Jake La Turner (R-Kan.) said yesterday he is concerned about PBMs "pickpocketing" health centers and other safety net providers' 340B savings.

A Kansas Republican congressman said on Capitol Hill yesterday that pharmacy benefit managers (PBMs) are taking away health centers and other safety net providers’ 340B savings and driving up their costs.

340B health centers and other providers “are reporting that

Read More »

For the First Time Since Pandemic, Some 340B Providers Are Being Audited in Person

HRSA has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.

The U.S. Health Resources and Services Administration (HRSA) has reconfirmed that it is auditing 340B covered entities for program compliance both remotely and in-person this fiscal year.

HRSA told 340B Report in mid-September that in October it would resume

Read More »

CMS Delays Implementing Rule Allowing Multiple Best Prices for Drugs Until Next July

CMS announced late today that they are reversing significant Medicare cuts to 340B hospitals.

The Biden administration said yesterday it is delaying by six months the effective date of a Trump administration final rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing (VBP)

Read More »

As Contract Pharmacy Losses Climb into the Billions, Fine for Overcharging 340B Providers Gets Closer to $6,000 Per Instance Mark

HHS OIG has raised the civil monetary penalty for overcharging a 340B covered entity to adjust for inflation.

The federal fine for overcharging a 340B covered entity just went up from $5,883.00 to $5,953.00 per each instance of overcharging.

The U.S. Health and Human Services Department (HHS) Office of Inspector General (OIG) posted its annual inflation adjustments to

Read More »

AstraZeneca and Feds Keep Sparring over 340B While Waiting for Judge to Rule

AstraZeneca and the federal government are awaiting the federal district court in Delaware's decision in the company’s 340B contract pharmacy lawsuit.

Drug manufacturer’s AstraZeneca and the federal government continue to joust in court as they await a crucial decision in the company’s 340B contract pharmacy lawsuit.

The two sides on Friday filed a joint status report in Astra’s lawsuit to

Read More »

Insulin and Diabetes Drug Makers Ask Judge to Dismiss 340B-Related Antitrust Charges

Insulin and diabetes drug manufacturers want a federal district judge to dismiss 340B-related antitrust changes against them.

U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.

In a Nov. 11 joint

Read More »

In What Could be the First of Many Challenges, Lilly Appealing U.S. District Court’s 340B Contract Pharmacy Ruling

Lilly yesterday filed notice that it is appealing a federal district judge's decision in its 340B contract pharmacy lawsuit.

Drug manufacturer Eli Lilly late yesterday filed notice that it is appealing a federal district judge’s Oct. 29 ruling partially in Lilly’s favor and partially for the federal government on the legality of Lilly’s denials of 340B ceiling prices when

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report